Abstract
Background A coronary artery calcium (CAC) score of 0 is widely considered to indicate low short- to intermediate-term risk for coronary artery disease (CAD) and is frequently used to defer lipid-lowering therapy. However, a subset of individuals with CAC=0 still experience events, highlighting residual risk not captured by imaging alone. Polygenic risk scores (PRS) quantify lifelong inherited susceptibility, but conventional approaches rely on predefined ancestry labels despite human genetic diversity existing along a continuum. To address this limitation, we developed 8 Billion, a novel, label-free framework that models genetic similarity without pre-labeling individuals by ancestry. We evaluated whether a CAD PRS derived using this approach identifies clinically meaningful residual risk among individuals with baseline CAC=0.
Methods We analyzed participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with baseline CAC=0. The 8 Billion framework estimates individualized PRS by anchoring each participant to a genetically similar reference neighborhood rather than discrete ancestry groups. Multivariable Cox proportional hazards models assessed associations between PRS-defined risk groups and incident CAD, adjusting for principal components of genetic variation (PC1–PC4), age, sex, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, diabetes, and antihypertensive medication use. Two classifications were evaluated: (1) a Top 5% group defined by the highest 5% of PRS-derived odds ratios in the cohort; and (2) an individualized high-risk group defined using a personalized threshold derived from the 8 Billion framework. Ten-year absolute risk estimates were derived from adjusted models.
Results Despite CAC=0 at baseline, polygenic burden was independently associated with incident CAD. Individuals in the Top 5% PRS group had higher risk of CAD events compared with the remainder (hazard ratio [HR], 3.12; 95% CI, 1.05–9.31; P=0.041). The individualized high-risk group defined through 8 Billion was similarly associated with increased CAD risk (HR, 2.52; 95% CI, 1.12–5.66; P=0.025). Estimated 10-year ASCVD risk among high-PRS individuals exceeded the 7.5% threshold commonly used to guide initiation of lipid-lowering therapy, despite CAC=0. In fully adjusted models, conventional risk factors were not statistically significant within this subset.
Conclusions Among individuals with CAC=0 in a multi-ethnic cohort, a label-free, ancestry-continuum PRS approach identified subgroups at significantly increased risk of incident CAD and at guideline-relevant 10-year treatment thresholds. Integration of polygenic risk with CAC imaging refines preventive decision-making beyond imaging alone.
What is new?
Among individuals with baseline CAC=0, the Allelica Multi-ancestry CAD PRS calculated with the 8 Billion framework identified subgroups at significantly increased risk of incident CAD.
In this CAC=0 population, high polygenic risk was associated with 10-year risk estimates above the 7.5% treatment threshold, whereas conventional risk factors were not statistically significant in adjusted models.
What are the clinical implications?
A CAC score of 0 should not be interpreted as uniformly protective, because genetically high-risk individuals may still experience clinically meaningful coronary events.
Integrating PRS with CAC assessment may improve preventive decision-making by identifying patients with residual risk despite reassuring baseline imaging.
In selected patients with CAC=0, high polygenic risk may support closer follow-up and earlier consideration of lipid-lowering therapy or other preventive strategies and imaging modalities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Allelica Inc
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Multi-Ethnic Study of Atherosclerosis (MESA) was approved by the Institutional Review Boards at all participating field centers and the coordinating center, and all participants provided written informed consent. The present analyses were conducted using de-identified data obtained through dbGaP under an approved data use agreement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Non-standard Abbreviations and Acronyms
- ACC
- American College of Cardiology AHA American Heart Association AMR Admixed American
- ASCVD
- atherosclerotic cardiovascular disease CAC coronary artery calcium
- CAD
- coronary artery disease CI confidence interval
- CVD
- cardiovascular disease EAS East Asian
- HDL
- high-density lipoprotein HR hazard ratio
- MESA
- Multi-Ethnic Study of Atherosclerosis OR odds ratio
- PC
- principal component
- PCE
- Pooled Cohort Equations PRS polygenic risk score
- SBP
- systolic blood pressure





